glp-1 medications tirzepatide Eli Lilly to seek approval of new weight-loss drug this year Understand GLP-1/GIP Dual Agonist Tirzepatide

The human body does not like dramatic weight loss

Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling

Brand-reported statistics (the 18 percent, 9 out of 10, 6.5 inch, and 84 percent figures) are presented as brand-stated and not independently audited

Approved for chronic weight management